Free Trial

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$18.80 +0.86 (+4.79%)
Closing price 04:00 PM Eastern
Extended Trading
$18.59 -0.21 (-1.12%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$17.68
$18.85
50-Day Range
$11.93
$43.01
52-Week Range
$10.41
$144.22
Volume
7.53 million shs
Average Volume
6.07 million shs
Market Capitalization
$1.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.17
Consensus Rating
Hold

Company Overview

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 170th out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 8 buy ratings, 16 hold ratings, and 5 sell ratings.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 27 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is -21.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is -21.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    15.21% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 1.23%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.21% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 1.23%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 62 news articles for Sarepta Therapeutics this week, compared to 67 articles on an average week.
  • Search Interest

    146 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 132% compared to the previous 30 days.
  • MarketBeat Follows

    24 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 85% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.60% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Konskie, Poland - December 14, 2024: Sarepta Therapeutics company logo displayed on mobile phone — Stock Editorial Photography
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics.
Game Over for Tesla?
Tesla is down 50% from its highs, and recent SEC filings reveal major insider selling—tens of millions in stock unloaded by top executives. Meanwhile, Elon Musk appears to be shifting focus away from Tesla and toward his private AI venture, xAI. Musk has already purchased over $1 billion in NVIDIA AI chips and is investing $5 billion into a new data center. Our research shows xAI is growing 7X faster than OpenAI—and could be the source of the next wave of AI millionaires.
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $121.59 at the start of the year. Since then, SRPT stock has decreased by 84.5% and is now trading at $18.80.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings results on Wednesday, August, 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. The company's revenue for the quarter was up 68.4% on a year-over-year basis.

Sarepta Therapeutics subsidiaries include Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Sarepta Therapeutics' top institutional investors include Geode Capital Management LLC (1.91%), Aberdeen Group plc (1.26%), Y Intercept Hong Kong Ltd (0.89%) and Assenagon Asset Management S.A. (0.88%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor.
View institutional ownership trends
.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
8/06/2025
Today
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
CIK
873303
Employees
1,372
Year Founded
1980

Price Target and Rating

High Price Target
$150.00
Low Price Target
$13.00
Potential Upside/Downside
+147.4%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
29 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.69
P/E Growth
N/A
Net Income
$235.24 million
Net Margins
-2.34%
Pretax Margin
-0.97%
Return on Equity
-1.03%
Return on Assets
-0.37%

Debt

Debt-to-Equity Ratio
0.84
Current Ratio
2.89
Quick Ratio
1.81

Sales & Book Value

Annual Sales
$1.90 billion
Price / Sales
0.92
Cash Flow
$2.39 per share
Price / Cash Flow
7.48
Book Value
$15.99 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
97,710,000
Free Float
90,287,000
Market Cap
$1.74 billion
Optionable
Optionable
Beta
0.46

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners